Formerly dba Cardiovascular Simulation, Inc., HeartFlow, Inc. is described as a personalized medical technology company seeking to transform the way cardiovascular disease is diagnosed and treated. Grounded in 15 years of scientific investigation by the firm's principals at Stanford and with a very limited SBIR presence, the companys FFRCT Analysis is a non-invasive solution that enables a physician more accurately to evaluate whether a patient has significant coronary artery disease (CAD) based on both anatomy and physiology. HeartFlows technology enables the computation of FFRCT in a non-invasive manner by using computed tomography (CT) scans and high-performance computing to provide physicians with data about blood flow within the coronary arteries.
